Featured Research

from universities, journals, and other organizations

Modified proteins as vaccines against peach allergy

Date:
January 20, 2014
Source:
Universidad Politécnica de Madrid
Summary:
Research has been conducted on the peach allergy, the most common food allergy, and the Pru p 3 protein. As a result of this research work, three hypoallergenic variants of this protein have been developed, including a potential vaccine.

A research conducted by the Centre for Plant Biotechnology and Genomics (UPM-INIA) and led by Araceli Díaz Perales has studied the allergy to peach, the most common food allergy, and the Pru p 3 protein. As a result of this research work, they have developed three hypoallergenic variants of this protein. All can be good candidates for the usage of specific immunotherapy for peach allergy and also can be used as a vaccine.

Nowadays, allergy affects over 25% of the population of developed countries. Currently, the treatment of food allergy consists of avoiding the intake of the food causing the allergy. However, the possibility of cross-reactivity (reaction to related food) might be ineffective.

The specific immunotherapy is the only treatment to prevent more severe signs of allergy progression. Immunotherapy consists of the intake of growing doses of allergen extracts in affected patients. However, the use of this extract could induce anaphylactic reactions or lead to sensitization to new allergens found in the mixture of allergen extracts. According to this, the usage of hypoallergenic molecules (with lower ability of binding antibodies) but with the ability to stimulate the immune system, would be a useful tool for immunotherapy.

The most common food allergy in Spain and the Mediterranean areas is the peach allergy which is mainly caused by the Pru p 3 proteins. The current treatment of this allergy consists of avoiding peach consumption, neither fresh nor processed peaches (juices jam). As an alternative, this allergy research has defined the regions of this allergenic protein that is involved in the antibody binding and the stimulation of the immune system cells. After that, researchers developed three hypoallergenic variants of this protein that can be used as a vaccine.

These variants are the result of modifying epitopes (regions of binding antibodies) of this protein and they were used in a research with patient allergic to peach in order to confirm its capacity as immune system stimulation. Each variant has a different modification that was designed by using genetic tools. Although the 1 variant (Pru p 3.01) showed quite similar allergenic activity with the natural protein, the variants Pru p 3.02 and Pru p 3.03 presented lower capacity for binding antibodies. Also, it maintained its ability to stimulate immune system cells (lymphocytes) of the patients allergic to peach during the in vitro trials.

The results show that these two molecules (Pru p 3.02 and Pru p 3.03) could be good candidates for the usage of specific immunotherapy for allergy to peach.

This research work has established the basis to set a new immunotherapy strategy although it would be required further trials of these two molecules with animal to verify its effectiveness in the treatment for allergy to peach.


Story Source:

The above story is based on materials provided by Universidad Politécnica de Madrid. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Gómez-Casado, M. Garrido-Arandia, P. Gamboa, N. Blanca-López, G. Canto, J. Varela, J. Cuesta-Herranz, L. F. Pacios, A. Díaz-Perales, L. Tordesillas. Allergenic Characterization of New Mutant Forms of Pru p 3 as New Immunotherapy Vaccines. Clinical and Developmental Immunology, 2013; 2013: 1 DOI: 10.1155/2013/385615

Cite This Page:

Universidad Politécnica de Madrid. "Modified proteins as vaccines against peach allergy." ScienceDaily. ScienceDaily, 20 January 2014. <www.sciencedaily.com/releases/2014/01/140120090426.htm>.
Universidad Politécnica de Madrid. (2014, January 20). Modified proteins as vaccines against peach allergy. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/01/140120090426.htm
Universidad Politécnica de Madrid. "Modified proteins as vaccines against peach allergy." ScienceDaily. www.sciencedaily.com/releases/2014/01/140120090426.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins